U.S. court affirms Sanofi's Eloxatin patent until 2012

Sanofi's ($SNY) Eloxatin is safe from generic competition in the U.S. until August 2012. A federal court denied Sun Pharmaceuticals' appeal in a patent dispute over the colon cancer drug, which brought in $349 million in the the second quarter, Reuters said. Report

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.